In this article, we will take a look at the 10 Fast-Growing AI Healthcare Companies to Watch Right Now.
Artificial intelligence in healthcare is no longer limited to futuristic robots or experimental laboratory software. It is already helping interpret medical images, analyze billions of genetic data points, identify traces of cancer in blood, automate clinical documentation and guide surgeons through increasingly complex procedures. One fascinating detail is that the human genome contains roughly three billion DNA base pairs—far too much information to assess manually at scale, but exactly the kind of data challenge that machine learning was built to handle.
The technology is also becoming smaller and more accessible. Ultrasound systems that once occupied large hospital rooms can now fit inside a clinician’s hand, while liquid-biopsy platforms can search a simple blood sample for microscopic fragments of tumor DNA. Robotic surgical systems, despite their name, still do not operate independently; they translate a surgeon’s movements into more precise actions while generating valuable procedural data that may improve future training and clinical decisions.
Why AI Healthcare Stocks Are Attracting Investors
For Wall Street, the attraction goes beyond clever algorithms. The most promising AI healthcare companies are beginning to generate real revenue from precision medicine, genomic testing, medical imaging, digital health platforms, cancer diagnostics and robotic-assisted surgery. This commercial progress is separating legitimate healthcare AI stocks from companies that merely attach the AI label to an otherwise ordinary business.
Still, the sector is not a guaranteed prescription for profits. Many fast-growing artificial intelligence healthcare stocks remain unprofitable, and even the strongest businesses face regulatory approvals, insurance reimbursement challenges, expensive research programs and demanding valuations. Against that backdrop, the 10 Fast-Growing AI Healthcare Companies to Watch Right Now highlights NYSE- and Nasdaq-listed businesses showing some of the most compelling combinations of technological relevance, commercial adoption and financial growth.
CHECK THIS OUT: Top 10 Healthcare Stocks to Buy With $1000 in 2026 and 10 Best Medicine Stocks That Could Make Investors 100% Richer.
Our Methodology
To rank the 10 Fast-Growing AI Healthcare Companies to Watch Right Now, we evaluated NYSE- and Nasdaq-listed companies based on revenue growth, AI relevance, commercial adoption, financial strength, competitive advantages and overall investment risk.
10 Fast-Growing AI Healthcare Companies to Watch Right Now
10. Doximity Inc. (NYSE:DOCS)
Doximity, Inc. (NYSE: DOCS) opens the ranking as one of the most established digital platforms serving American physicians and healthcare professionals.
The platform is sometimes described as a professional network for doctors, but its business now extends well beyond professional profiles and medical news. It provides secure patient communication, telehealth, clinical collaboration, electronic prescribing and workflow-management products.
Artificial intelligence is becoming increasingly important to that ecosystem. The company has introduced AI-powered clinical search, automated note-taking and tools that can assist physicians in preparing medical documentation and patient communications.
That is strategically significant because the company does not need to build a healthcare audience from scratch. It already has an extensive network of medical professionals who can adopt these artificial intelligence healthcare tools within workflows they use regularly.
More than 800,000 active prescribers reportedly used its workflow tools during the fiscal fourth quarter. Nearly half of those providers also used its clinical AI products, while prompts per user almost doubled between January and April.
However, the business has recently struggled to convert rapidly rising AI engagement into equally impressive revenue growth. Fiscal fourth-quarter revenue increased only 5% year over year to approximately $145.4 million. Management’s fiscal 2027 revenue forecast of between $664 million and $676 million also came in below Wall Street expectations.
The company remains highly profitable compared with most emerging healthcare AI companies, but its near-term growth profile is no longer as strong as it was in previous years. That is why it enters the list at No. 10 rather than challenging the faster-growing diagnostic and medical-imaging businesses.
The long-term opportunity is still attractive. If clinical AI becomes a routine tool for physicians, the company’s existing professional network could become an exceptionally effective distribution channel. Investors must simply wait for rising AI usage to produce a more visible financial contribution.
